BioNova Pharmaceuticals Announces Collaboration with Insilico Medicine to Discover Small Molecule Target Inhibitors

SHANGHAI, August 20, 2021 -- BioNova Pharmaceuticals (Shanghai) Ltd. (**BioNova**), a fast-growing biopharmaceutical company that is committed in developing and commercializing innovative medicines for cancer and other life-threatening diseases, and Insilico Medicine (**Insilico**), an industry-leading artificial intelligence-driven drug discovery company, today announced entry into a collaboration agreement to jointly discover small molecule inhibitors by targeting oncogenic pathways, which are believed to be dominant drivers of specific hematologic malignancies.

Pursuant to the agreement, the collaboration will leverage a BioNova discovery stage project and the company's deep knowledge and understanding of molecular targets and unmet medical needs, in combination with Insilico's artificial intelligence (AI)-powered drug discovery platform based on deep reinforcement learning technology and mass data training. The two parties will apply cutting-edge molecular design methods to improve the efficiency and success rate of drug discovery and development to develop best-in-class small molecule compounds for hematological malignancies.

"Early drug discovery work is typically time-consuming with low success rate. However, in recent years, AI-powered drug discovery platforms have emerged as an effective tool that showed brilliant application potential." said Ye Hua, MD, MPH, CEO of BioNova, "As an AI-powered drug discovery pioneer, Insilico's unique platform can significantly increase the efficiency and success rate of drug discovery. With Insilico's platform and technology in combination with BioNova's strengths and expertise in drug development, we believe such supplemental collaboration will create synergistic value to expedite BioNova's innovative drug discovery and early development."

"BioNova is a top-tier clinical-stage biopharmaceutical company with a strong novel drug development team and excellent innovation capability. This cooperation may give full play to Insilico's AI-powered drug discovery platform based on mass data and a unique generation model and combine BioNova's integrated innovation in development, covering areas from translational medicine to clinical trials. Thus, provide highly efficient solutions for diseases with unmet medical need." said Feng Ren, PhD, Chief Scientific Officer and Head of Drug Discovery of Insilico.

About BioNova
BioNova Pharmaceuticals (Shanghai) Ltd. is a privately-held clinical-stage biopharmaceutical company dedicated to the development and commercialization of innovative medicines for cancer and other life-threatening diseases with high unmet medical needs. Headquartered in Shanghai, BioNova is a fast-growing company with a robust pipeline built on internal R&D programs, collaborations with, and acquisitions from partners of cutting-edge technology. With a highly capable and seasoned team in combination with substantial funding, BioNova is committed to delivering high-quality innovative medicines to patients in China and globally.
For further information, please refer to https://www.bionovapharma.com

About Insilico Medicine
Insilico Medicine, an end-to-end artificial intelligence-driven drug discovery company, is developing artificial intelligence platforms. These platforms use deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, infectious diseases, autoimmune diseases, and age-related diseases.

For further information, please refer to www.insilico.com

Contact Us
Claire Shan
IR & PR Manager
Email: claire.shan@bionovapharma.com
Tel: +86 (21) 5090 1280
Add: 2889 Jinke Road, Chamtime Plaza, Building B, Suite 905, Shanghai 201203, China